← Oncology Approval Tracker

FDA DECISION ·

Opdivo

nivolumab · Bristol Myers Squibb

FDA approvalNew or expanded indicationEsophageal and gastroesophageal junction cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adjuvant therapy after complete resection of esophageal or gastroesophageal junction cancer with residual pathologic disease after neoadjuvant chemoradiotherapy.

LAMPGEN ANALYSIS

Why it matters

Residual disease after multimodality treatment defines this postoperative indication.

What research teams should watch

Reconcile preoperative chemoradiation, margin status, residual disease and surgery date.

PRIMARY RECORDS

Sources